The “bottleneck” of current gene therapy approaches is the lack of an efficient gene delivery system. Retroviral vectors have been very useful for ex vivo gene delivery, but suffer two major ...

Current lentiviral vector systems (the third generation) generate virus particles using four plasmids and a producer cell line. The rationale behind four plasmids is to enhance safety, as ...

In one of the largest private rounds raised by an Italian biotech, Genespire Srl has closed a €46.6 million (US$51.88 million) series B, enabling it to lay the ground for a phase I/II clinical trial ...

1996a) (Naldini et al., 1996b) , the vector pCMVΔR8.2 supplies all but the HIV envelope in trans, the vector pMD.G is used to produce the VSV-G pseudotype, while the transgene (lac Z) is inserted into ...

Download this application note from Thermo Fisher Scientific to learn how scientists have used their lentiviral production system, single-use bioreactors, and clarification products to generate ...

FRIDAY, Oct. 11, 2024 (HealthDay News) -- For boys with early-stage cerebral adrenoleukodystrophy and evidence of active ...

Wells Fargo analyst Tiago Fauth has maintained their bullish stance on TECX stock, giving a Buy rating yesterday. Tiago Fauth has given his ...

The company faces supply constraints and prioritizes markets like the U.S. and Europe over China due to limited availability ...

In a report released on November 8, David Risinger from Leerink Partners maintained a Buy rating on Tectonic Therapeutic (TECX – Research ...

PARIS--(BUSINESS WIRE)--TheraVectys, a biotechnology company that designs and develops lentiviral vector-based vaccines and immunotherapies against infectious agents and cancers, announces that ...

Ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech reports third quarter 2024 financial results. (Operator Instructions) Please be advised that today's conference is being ...

All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and ...